N
NRIX icon

Nuveen’s Nurix Therapeutics NRIX Stock Holding History

Nuveen’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$12.6M Buy
812,601
+28,192
+4% +$467K ﹤0.01% 1421
2025
Q4 		$14.9M Buy
784,409
+632,349
+416% +$9.08M ﹤0.01% 1316
2025
Q3 		$1.41M Hold
152,060
– – ﹤0.01% 2456
2025
Q2 		$1.73M Sell
152,060
-17,085
-10% -$185K ﹤0.01% 2369
2025
Q1 		$2.01M Sell
169,145
-240,492
-59% -$4.02M ﹤0.01% 2336
2024
Q4 		$7.72M Sell
409,637
-263,917
-39% -$6.05M ﹤0.01% 1741
2024
Q3 		$15.1M Sell
673,554
-307,613
-31% -$6.97M ﹤0.01% 1365
2024
Q2 		$20.5M Buy
981,167
+562,344
+134% +$8.76M 0.01% 1111
2024
Q1 		$6.16M Sell
418,823
-115,042
-22% -$1.24M ﹤0.01% 1867
2023
Q4 		$5.51M Sell
533,865
-129,395
-20% -$887K ﹤0.01% 1923
2023
Q3 		$5.21M Sell
663,260
-4,157
-0.6% -$38K ﹤0.01% 1847
2023
Q2 		$6.67M Sell
667,417
-2,556
-0.4% -$26.1K ﹤0.01% 1757
2023
Q1 		$5.95M Sell
669,973
-20,392
-3% -$213K ﹤0.01% 1791
2022
Q4 		$7.58M Buy
690,365
+137,709
+25% +$1.66M ﹤0.01% 1671
2022
Q3 		$7.2M Buy
552,656
+228,071
+70% +$3.61M ﹤0.01% 1683
2022
Q2 		$4.11M Buy
324,585
+219,194
+208% +$2.48M ﹤0.01% 2073
2022
Q1 		$1.44M Buy
105,391
+10,614
+11% +$188K ﹤0.01% 2664
2021
Q4 		$2.49M Sell
94,777
-7,082
-7% -$215K ﹤0.01% 2464
2021
Q3 		$3.67M Sell
101,859
-46,900
-32% -$1.45M ﹤0.01% 2374
2021
Q2 		$3.95M Buy
148,759
+8,702
+6% +$255K ﹤0.01% 2360
2021
Q1 		$4.35M Buy
140,057
+41,216
+42% +$1.56M ﹤0.01% 2229
2020
Q4 		$3.25M Buy
98,841
+31,991
+48% +$1.06M ﹤0.01% 2272
2020
Q3 		$2.33M Buy
+66,850
New +$1.68M ﹤0.01% 2301

Other funds holding NRIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
GA
General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return

Nuveen's NRIX Position: Q1 2026 in Review

Nuveen increased its Nurix Therapeutics (NRIX) stake by 3.6% in Q1 2026, buying an estimated $467K and bringing the position to 812,601 shares worth $12.6M. The position accounts for ﹤0.01% of the portfolio, ranked #1421.

Nuveen first reported a position in NRIX in Q3 2020 and has held it in 23 quarters since. The position peaked at $20.5M in Q2 2024. 195 funds tracked by Wall St. Rank hold NRIX as of Q1 2026.

  • Nuveen held 812,601 shares of Nurix Therapeutics worth $12.6M as of Q1 2026.
  • Nuveen bought 28,192 Nurix Therapeutics shares in Q1 2026, an estimated $467K.
  • Nurix Therapeutics made up ﹤0.01% of Nuveen's portfolio in Q1 2026, its #1421 holding.
  • Nuveen first reported a position in Nurix Therapeutics in Q3 2020 and has held it in 23 quarters since.
  • Nuveen's Nurix Therapeutics position peaked at $20.5M in Q2 2024.
  • 195 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q1 2026.

Based on Nuveen's 13F filing for Q1 2026, filed 30 Apr 2026.